RxDoctor Payments Data

Mehrdad Tavallaee, MD

Internal Medicine · Ashland, OHNPI 1689625634

Payments from drug & device makers

$5,213in general payments, 2019–2025

Across 315 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$651
  • AstraZeneca$445
  • Johnson & Johnson$349
  • Boehringer Ingelheim$325
  • GSK$283
  • Amgen$267
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$5,18399%
  • Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,213 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$277,643
Medicare patients
603
Services billed
3,657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,025$449,958
JardianceEmpagliflozin191$191,114
NuplazidPimavanserin Tartrate59$167,595
AustedoDeutetrabenazine31$144,290
OzempicSemaglutide126$119,755
Invega SustennaPaliperidone Palmitate19$62,970
XareltoRivaroxaban83$61,747
CreonLipase/Protease/Amylase51$58,841
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr115$55,238
JanuviaSitagliptin Phosphate55$53,472
FarxigaDapagliflozin Propanediol70$52,402
TrulicityDulaglutide51$48,611
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$45,169
EntrestoSacubitril/Valsartan82$44,092
MyrbetriqMirabegron56$28,677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$207$449,9581,025 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$325$234,458288 claims
Acadia Pharmaceuticals IncNuplazid$33$167,59559 claims
Teva Pharmaceuticals USA, Inc.Austedo$217$144,29031 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta, Shingrix$283$125,358264 claims
Johnson & JohnsonInvega Sustenna, Xarelto$349$124,717102 claims
Novo NordiskOzempic$229$119,755126 claims
AbbVieCreon, Linzess, Namzaric$651$86,369126 claims
AstraZenecaFarxiga, Symbicort$445$61,06684 claims
Lilly USA, LLCTrulicity$62$48,61151 claims
NovartisEntresto$123$44,09282 claims
Astellas Pharma US IncMyrbetriq$50$28,67756 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Ashland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →